

Remarks


The Examiner found that Applicants' claims were directed to patentably distinct species in respect of the type of (I) medicaments, (II) dispersing agents, (III) superdisintegrants, (IV) distributing agents and (V) binders employed in one or more of Applicants' claims. Within each category, Applicants were required to elect a single species in order for prosecution on the merits to proceed. The Examiner further apprised Applicants that if no generic claim is found allowable, the claims would be restricted to such species.

Applicants herein provisionally elect a species with traverse as set forth below and respectfully request reconsideration being that the generic claim includes sufficiently few species that search and examination of all the species does not constitute a serious burden. Accordingly, Applicants elect (I) aripiprazole as the medicament species, (II) alpha triclinic calcium silicate as the dispersing agent species, (III) crospovidone as the superdisintegrant species, (IV) amorphous silica as the distributing agent species and (V) microcrystalline cellulose as the binder species. Applicants believe that claims 1-7, 9-14, 16, 20-48 read on the elected species.

In respect of the above, Applicants respectfully request reconsideration and examination to proceed on the merits.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7268

Respectfully submitted,



Shah R. Makujina
Attorney for Applicants
Reg. No. 41,174